$APLS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Apellis Pharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Apellis Pharmaceuticals, Inc.. Get notifications about new insider transactions in Apellis Pharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 25 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | M | 2.67 | 6,250 | 16,688 | 368,999 | |
| Jun 25 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Sell | S | 65.61 | 6,250 | 410,063 | 869,587 | 875.8 K to 869.6 K (-0.71 %) |
| Jun 25 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Buy | M | 2.67 | 6,250 | 16,688 | 875,837 | 869.6 K to 875.8 K (+0.72 %) |
| Jun 16 2021 | APLS | Apellis Pharmaceut ... | DeLong Mark Jeffrey | Senior Vice Preside ... | Option Exercise | M | 15.52 | 4,000 | 62,080 | 44,000 | |
| Jun 16 2021 | APLS | Apellis Pharmaceut ... | DeLong Mark Jeffrey | Senior Vice Preside ... | Sell | S | 64.96 | 4,000 | 259,830 | 9,490 | 13.5 K to 9.5 K (-29.65 %) |
| Jun 16 2021 | APLS | Apellis Pharmaceut ... | DeLong Mark Jeffrey | Senior Vice Preside ... | Buy | M | 15.52 | 4,000 | 62,080 | 13,490 | 9.5 K to 13.5 K (+42.15 %) |
| Jun 02 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Buy | J | 0.00 | 2,682 | 0 | 303,361 | 300.7 K to 303.4 K (+0.89 %) |
| Jun 02 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Buy | J | 0.00 | 13,108 | 0 | 73,108 | 60 K to 73.1 K (+21.85 %) |
| Jun 02 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Sell | J | 0.00 | 31,855 | 0 | 0 | 31.9 K to 0 (-100.00 %) |
| May 25 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | M | 2.67 | 6,250 | 16,688 | 375,249 | |
| May 25 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Sell | S | 47.40 | 6,250 | 296,250 | 869,587 | 875.8 K to 869.6 K (-0.71 %) |
| May 25 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Buy | M | 2.67 | 6,250 | 16,688 | 875,837 | 869.6 K to 875.8 K (+0.72 %) |
| May 04 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Option Exercise | M | 3.76 | 1,000 | 3,760 | 9,161 | |
| May 04 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Sell | S | 50.73 | 1,000 | 50,730 | 4,847 | 5.8 K to 4.8 K (-17.10 %) |
| May 04 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Buy | M | 3.76 | 1,000 | 3,760 | 5,847 | 4.8 K to 5.8 K (+20.63 %) |
| May 04 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 50.73 | 600 | 30,438 | 55,614 | 56.2 K to 55.6 K (-1.07 %) |
| May 03 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Option Exercise | M | 3.76 | 1,000 | 3,760 | 10,161 | |
| May 03 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Sell | S | 50.00 | 1,000 | 50,000 | 4,847 | 5.8 K to 4.8 K (-17.10 %) |
| May 03 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Buy | M | 3.76 | 1,000 | 3,760 | 5,847 | 4.8 K to 5.8 K (+20.63 %) |
| Apr 29 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | M | 2.67 | 4,500 | 12,015 | 381,499 | |
| Apr 29 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Buy | M | 2.67 | 4,500 | 12,015 | 869,587 | 865.1 K to 869.6 K (+0.52 %) |
| Apr 26 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | M | 2.67 | 6,250 | 16,688 | 385,999 | |
| Apr 26 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Sell | S | 46.13 | 6,250 | 288,313 | 865,087 | 871.3 K to 865.1 K (-0.72 %) |
| Apr 26 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Buy | M | 2.67 | 6,250 | 16,688 | 871,337 | 865.1 K to 871.3 K (+0.72 %) |
| Apr 26 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Option Exercise | M | 14.00 | 10,000 | 140,000 | 61,894 | |
| Apr 26 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Buy | M | 14.00 | 10,000 | 140,000 | 60,000 | 50 K to 60 K (+20.00 %) |
| Apr 22 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Option Exercise | M | 2.67 | 2,500 | 6,675 | 147,529 | |
| Apr 22 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Sell | S | 45.76 | 2,500 | 114,400 | 669,544 | 672 K to 669.5 K (-0.37 %) |
| Apr 22 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Buy | M | 2.67 | 2,500 | 6,675 | 672,044 | 669.5 K to 672 K (+0.37 %) |
| Apr 19 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Option Exercise | M | 14.00 | 50,000 | 700,000 | 71,894 | |
| Apr 19 2021 | APLS | Apellis Pharmaceut ... | Dunlop A. Sinclair | Director | Buy | M | 14.00 | 50,000 | 700,000 | 50,000 | 0 to 50 K |
| Apr 15 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 42.82 | 500 | 21,410 | 56,214 | 56.7 K to 56.2 K (-0.88 %) |
| Apr 05 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 43.41 | 600 | 26,046 | 56,714 | 57.3 K to 56.7 K (-1.05 %) |
| Mar 29 2021 | APLS | Apellis Pharmaceut ... | Brown Victoria L. | Program Team Lead | Payment of Exercise | F | 41.16 | 82 | 3,375 | 9,952 | 10 K to 10 K (-0.82 %) |
| Mar 23 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | M | 4.31 | 978 | 4,215 | 2,421 | |
| Mar 23 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Buy | M | 4.31 | 978 | 4,215 | 96,772 | 95.8 K to 96.8 K (+1.02 %) |
| Mar 19 2021 | APLS | Apellis Pharmaceut ... | Brown Victoria L. | Program Team Lead | Option Exercise | A | 47.68 | 7,500 | 357,600 | 7,500 | |
| Mar 19 2021 | APLS | Apellis Pharmaceut ... | Brown Victoria L. | Program Team Lead | Grant | A | 0.00 | 1,250 | 0 | 10,034 | 8.8 K to 10 K (+14.23 %) |
| Mar 17 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Option Exercise | M | 2.67 | 2,500 | 6,675 | 150,029 | |
| Mar 17 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Sell | S | 46.77 | 2,500 | 116,925 | 669,544 | 672 K to 669.5 K (-0.37 %) |
| Mar 17 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Buy | M | 2.67 | 2,500 | 6,675 | 672,044 | 669.5 K to 672 K (+0.37 %) |
| Mar 11 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | M | 2.67 | 6,250 | 16,688 | 392,249 | |
| Mar 11 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Sell | S | 50.74 | 6,250 | 317,125 | 865,087 | 871.3 K to 865.1 K (-0.72 %) |
| Mar 11 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Buy | M | 2.67 | 6,250 | 16,688 | 871,337 | 865.1 K to 871.3 K (+0.72 %) |
| Mar 08 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | M | 3.20 | 5,000 | 16,000 | 34,073 | |
| Mar 08 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 48.62 | 5,000 | 243,075 | 57,814 | 62.8 K to 57.8 K (-7.96 %) |
| Mar 08 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Buy | M | 3.20 | 5,000 | 16,000 | 62,814 | 57.8 K to 62.8 K (+8.65 %) |
| Mar 03 2021 | APLS | Apellis Pharmaceut ... | Eisele Jeffrey | Exec VP, Program Te ... | Option Exercise | A | 47.68 | 7,500 | 357,600 | 7,500 | |
| Mar 03 2021 | APLS | Apellis Pharmaceut ... | Eisele Jeffrey | Exec VP, Program Te ... | Grant | A | 0.00 | 1,250 | 0 | 7,461 | 6.2 K to 7.5 K (+20.13 %) |
| Mar 03 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 48.58 | 600 | 29,148 | 57,814 | 58.4 K to 57.8 K (-1.03 %) |
| Feb 17 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 46.00 | 500 | 23,000 | 58,414 | 58.9 K to 58.4 K (-0.85 %) |
| Feb 17 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Option Exercise | M | 2.67 | 2,500 | 6,675 | 152,529 | |
| Feb 17 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Sell | S | 46.00 | 2,500 | 115,000 | 669,544 | 672 K to 669.5 K (-0.37 %) |
| Feb 17 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Buy | M | 2.67 | 2,500 | 6,675 | 672,044 | 669.5 K to 672 K (+0.37 %) |
| Feb 11 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Payment of Exercise | F | 47.72 | 680 | 32,450 | 29,290 | 30 K to 29.3 K (-2.27 %) |
| Feb 11 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Payment of Exercise | F | 47.72 | 858 | 40,944 | 34,261 | 35.1 K to 34.3 K (-2.44 %) |
| Feb 11 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Payment of Exercise | F | 47.72 | 688 | 32,831 | 865,087 | 865.8 K to 865.1 K (-0.08 %) |
| Feb 11 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Payment of Exercise | F | 47.72 | 688 | 32,831 | 18,865 | 19.6 K to 18.9 K (-3.52 %) |
| Feb 11 2021 | APLS | Apellis Pharmaceut ... | Brown Victoria L. | Program Team Lead | Payment of Exercise | F | 47.72 | 144 | 6,872 | 8,784 | 8.9 K to 8.8 K (-1.61 %) |
| Feb 11 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Payment of Exercise | F | 47.72 | 468 | 22,333 | 95,794 | 96.3 K to 95.8 K (-0.49 %) |
| Feb 10 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Option Exercise | M | 3.76 | 2,000 | 7,520 | 13,161 | |
| Feb 10 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Sell | S | 50.00 | 2,000 | 100,000 | 2,500 | 4.5 K to 2.5 K (-44.44 %) |
| Feb 10 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Buy | M | 3.76 | 2,000 | 7,520 | 4,500 | 2.5 K to 4.5 K (+80.00 %) |
| Feb 02 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 44.00 | 600 | 26,400 | 59,602 | 60.2 K to 59.6 K (-1.00 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Grant | A | 0.00 | 1,875 | 0 | 19,553 | 17.7 K to 19.6 K (+10.61 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Grant | A | 0.00 | 7,500 | 0 | 17,678 | 10.2 K to 17.7 K (+73.69 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Grant | A | 0.00 | 1,875 | 0 | 60,202 | 58.3 K to 60.2 K (+3.21 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Grant | A | 0.00 | 7,500 | 0 | 58,327 | 50.8 K to 58.3 K (+14.76 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Grant | A | 0.00 | 1,875 | 0 | 19,553 | 17.7 K to 19.6 K (+10.61 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Townsend Adam J. | Chief Commercial Of ... | Grant | A | 0.00 | 7,500 | 0 | 17,678 | 10.2 K to 17.7 K (+73.69 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Option Exercise | A | 44.90 | 75,000 | 3,367,500 | 75,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Option Exercise | A | 44.90 | 150,000 | 6,735,000 | 150,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Grant | A | 0.00 | 12,500 | 0 | 1,222,356 | 1.2 M to 1.2 M (+1.03 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 1,209,856 | 1.2 M to 1.2 M (+2.11 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Option Exercise | A | 44.90 | 22,500 | 1,010,250 | 22,500 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Grant | A | 0.00 | 1,875 | 0 | 60,202 | 58.3 K to 60.2 K (+3.21 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Grant | A | 0.00 | 7,500 | 0 | 58,327 | 50.8 K to 58.3 K (+14.76 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Grant | A | 0.00 | 3,750 | 0 | 35,119 | 31.4 K to 35.1 K (+11.95 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 31,369 | 23.9 K to 31.4 K (+31.42 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Option Exercise | A | 44.90 | 75,000 | 3,367,500 | 75,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Option Exercise | A | 44.90 | 150,000 | 6,735,000 | 150,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Grant | A | 0.00 | 12,500 | 0 | 1,222,356 | 1.2 M to 1.2 M (+1.03 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 1,209,856 | 1.2 M to 1.2 M (+2.11 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Grant | A | 0.00 | 1,875 | 0 | 96,262 | 94.4 K to 96.3 K (+1.99 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Option Exercise | A | 44.90 | 22,500 | 1,010,250 | 22,500 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Grant | A | 0.00 | 7,500 | 0 | 94,387 | 86.9 K to 94.4 K (+8.63 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Grant | A | 0.00 | 3,750 | 0 | 35,119 | 31.4 K to 35.1 K (+11.95 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Sullivan Timothy Eugene | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 31,369 | 23.9 K to 31.4 K (+31.42 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Grant | A | 0.00 | 1,875 | 0 | 29,970 | 28.1 K to 30 K (+6.67 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Grant | A | 0.00 | 7,500 | 0 | 28,095 | 20.6 K to 28.1 K (+36.42 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Grant | A | 0.00 | 1,875 | 0 | 96,262 | 94.4 K to 96.3 K (+1.99 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Grant | A | 0.00 | 7,500 | 0 | 94,387 | 86.9 K to 94.4 K (+8.63 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Grant | A | 0.00 | 1,875 | 0 | 29,970 | 28.1 K to 30 K (+6.67 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | SCHEIBLER LUKAS | CHIEF INNOVATION OF ... | Grant | A | 0.00 | 7,500 | 0 | 28,095 | 20.6 K to 28.1 K (+36.42 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Nicholson Nur | Chief Technical Off ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Nicholson Nur | Chief Technical Off ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Nicholson Nur | Chief Technical Off ... | Grant | A | 0.00 | 1,875 | 0 | 9,375 | 7.5 K to 9.4 K (+25.00 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Nicholson Nur | Chief Technical Off ... | Grant | A | 0.00 | 7,500 | 0 | 7,500 | 0 to 7.5 K |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Lewis Karen | Chief People Office ... | Option Exercise | A | 44.90 | 7,500 | 336,750 | 7,500 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Lewis Karen | Chief People Office ... | Option Exercise | A | 44.90 | 30,000 | 1,347,000 | 30,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Lewis Karen | Chief People Office ... | Grant | A | 0.00 | 1,250 | 0 | 6,250 | 5 K to 6.3 K (+25.00 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Lewis Karen | Chief People Office ... | Grant | A | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Eisele Jeffrey | Exec VP, Program Te ... | Option Exercise | A | 44.90 | 30,000 | 1,347,000 | 30,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Eisele Jeffrey | Exec VP, Program Te ... | Grant | A | 0.00 | 5,000 | 0 | 6,211 | 1.2 K to 6.2 K (+412.88 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Brown Victoria L. | Program Team Lead | Option Exercise | A | 44.90 | 30,000 | 1,347,000 | 30,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Brown Victoria L. | Program Team Lead | Grant | A | 0.00 | 5,000 | 0 | 8,928 | 3.9 K to 8.9 K (+127.29 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Option Exercise | A | 44.90 | 15,000 | 673,500 | 15,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Perry Nicole D | Vice President - Ac ... | Grant | A | 0.00 | 2,500 | 0 | 2,500 | 0 to 2.5 K |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | A | 44.90 | 11,250 | 505,125 | 11,250 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Option Exercise | A | 44.90 | 45,000 | 2,020,500 | 45,000 | |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Grant | A | 0.00 | 1,875 | 0 | 865,775 | 863.9 K to 865.8 K (+0.22 %) |
| Feb 01 2021 | APLS | Apellis Pharmaceut ... | Deschatelets Pascal | Chief Scientific Of ... | Grant | A | 0.00 | 7,500 | 0 | 863,900 | 856.4 K to 863.9 K (+0.88 %) |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Option Exercise | M | 4.31 | 31,992 | 137,886 | 389,948 | |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Option Exercise | M | 3.76 | 39,785 | 149,592 | 273,840 | |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Buy | M | 4.31 | 31,992 | 137,886 | 1,184,856 | 1.2 M to 1.2 M (+2.78 %) |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Francois Cedric | Chief Executive Off ... | Buy | M | 3.76 | 39,785 | 149,592 | 1,152,864 | 1.1 M to 1.2 M (+3.57 %) |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | M | 4.31 | 20,042 | 86,381 | 3,399 | |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Option Exercise | M | 3.76 | 23,441 | 88,138 | 0 | |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Buy | M | 4.31 | 20,042 | 86,381 | 86,887 | 66.8 K to 86.9 K (+29.98 %) |
| Jan 29 2021 | APLS | Apellis Pharmaceut ... | Watson David O. | General Counsel | Buy | M | 3.76 | 23,441 | 88,138 | 66,845 | 43.4 K to 66.8 K (+54.01 %) |
| Jan 26 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | M | 3.76 | 11,500 | 43,240 | 23,661 | |
| Jan 26 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Option Exercise | M | 3.20 | 3,500 | 11,200 | 39,073 | |
| Jan 26 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Buy | M | 3.76 | 11,500 | 43,240 | 50,827 | 39.3 K to 50.8 K (+29.24 %) |
| Jan 26 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Buy | M | 3.20 | 3,500 | 11,200 | 39,327 | 35.8 K to 39.3 K (+9.77 %) |
| Jan 19 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Option Exercise | M | 2.67 | 2,500 | 6,675 | 155,029 | |
| Jan 19 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Sell | S | 53.15 | 2,500 | 132,875 | 669,544 | 672 K to 669.5 K (-0.37 %) |
| Jan 19 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Buy | M | 2.67 | 2,500 | 6,675 | 672,044 | 669.5 K to 672 K (+0.37 %) |
| Jan 15 2021 | APLS | Apellis Pharmaceut ... | Grossi Federico | CHIEF MEDICAL OFFIC ... | Sell | S | 51.99 | 4,000 | 207,960 | 35,827 | 39.8 K to 35.8 K (-10.04 %) |
| Jan 04 2021 | APLS | Apellis Pharmaceut ... | FONTEYNE PAUL R. | Director | Option Exercise | A | 57.20 | 27,600 | 1,578,720 | 27,600 | |
| Jan 04 2021 | APLS | Apellis Pharmaceut ... | Machiels Alec | Director | Option Exercise | A | 57.20 | 27,600 | 1,578,720 | 27,600 | |
| Jan 04 2021 | APLS | Apellis Pharmaceut ... | Chan Gerald | Director | Option Exercise | A | 57.20 | 27,600 | 1,578,720 | 27,600 | |
| Jan 04 2021 | APLS | Apellis Pharmaceut ... | O'Brien Stephanie Monaghan | Director | Option Exercise | A | 57.20 | 27,600 | 1,578,720 | 27,600 |